Withdrawal of Alupent

The short-acting bronchodilator orciprenaline sulphate (Alupent) is to be withdrawn over the next year, following an unfavourable risk-benefit analysis by the MHRA.

It concluded that the adverse events associated with the drug outweigh its clinical benefits.

Patients who are currently receiving Alupent should be switched to a more selective ß2-agonist, such as salbutamol or terbutaline, as soon as possible.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

New rapidly acting insulin launched

New rapidly acting insulin launched

Lyumjev is a new 'ultra rapidly acting' formulation...

Statin prescribing 'commonly breaching NICE guidance'

Statin prescribing 'commonly breaching NICE guidance'

Prescribing of suboptimal statin regimens is 'extremely...